ES2172764T3 - Modulacion de la expresion de citoquina th1/th2 por ribavirina en linfocitos t activados. - Google Patents
Modulacion de la expresion de citoquina th1/th2 por ribavirina en linfocitos t activados.Info
- Publication number
- ES2172764T3 ES2172764T3 ES97904765T ES97904765T ES2172764T3 ES 2172764 T3 ES2172764 T3 ES 2172764T3 ES 97904765 T ES97904765 T ES 97904765T ES 97904765 T ES97904765 T ES 97904765T ES 2172764 T3 ES2172764 T3 ES 2172764T3
- Authority
- ES
- Spain
- Prior art keywords
- expression
- activated
- cytokin
- ribavirine
- lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
Abstract
LA INVENCION SE REFIERE A LA ADMINISTRACION DE RIBAVIRINAR A UN PACIENTE EN UN RANGO DE DOSIFICACION EFECTIVO PARA MODULAR LA EXPRESION DE LA CITOQUINA EN CELULAS T ACTIVADAS. EN CONCRETO, LA RIBAVIRINA R SE UTILIZA PARA SUPRIMIR LAS RESPUESTAS DE LAS CELULAS T MEDIADAS POR TH-2 Y PROMOVER LA RESPUESTA DE DICHAS CELULAS MEDIADA POR TH-1. EN OTROS ASPECTOS DE LA INVENCION, SE ADMINISTRAN UNO O MAS ANALOGOS DE RIBAVIRINA R A UN PACIENTE, EN UN RANGO DE DOSIFICACION QUE ES EF ECTIVO PARA MODULAR LA EXPRESION DE LA LINFOQUINA EN CELULAS T ACTIVADAS. DICHOS ANALOGOS SE PUEDEN UTILIZAR PARA SUPRIMIR O FAVORECER LAS RESPUESTAS DE LAS CELULAS T MEDIADAS POR TH1 O TH2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/590,449 US5767097A (en) | 1996-01-23 | 1996-01-23 | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
US3609497P | 1997-01-17 | 1997-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2172764T3 true ES2172764T3 (es) | 2002-10-01 |
Family
ID=26712784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97904765T Expired - Lifetime ES2172764T3 (es) | 1996-01-23 | 1997-01-21 | Modulacion de la expresion de citoquina th1/th2 por ribavirina en linfocitos t activados. |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP0879056B1 (es) |
KR (1) | KR100298158B1 (es) |
CN (1) | CN1190198C (es) |
AT (1) | ATE216886T1 (es) |
BR (1) | BR9707154A (es) |
CA (1) | CA2246162C (es) |
CZ (1) | CZ293584B6 (es) |
DE (1) | DE69712316T2 (es) |
DK (1) | DK0879056T3 (es) |
ES (1) | ES2172764T3 (es) |
HU (1) | HU220105B (es) |
IL (1) | IL125088A0 (es) |
NO (1) | NO983372L (es) |
NZ (1) | NZ330784A (es) |
PL (1) | PL187439B1 (es) |
PT (1) | PT879056E (es) |
RU (1) | RU2186569C2 (es) |
SI (1) | SI9720013A (es) |
SK (1) | SK283342B6 (es) |
UA (1) | UA46815C2 (es) |
WO (1) | WO1997026883A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1302474A1 (en) * | 1996-10-16 | 2003-04-16 | Ribapharm, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
EP0938315B9 (en) | 1996-10-25 | 2008-02-20 | Minnesota Mining And Manufacturing Company | Immune response modifier compounds for treatment of th2 mediated and related diseases |
HUP0200027A2 (en) * | 1999-01-29 | 2002-04-29 | Icn Pharmaceuticals | Modulation of immune response by ribavirin |
US7638496B2 (en) | 2000-02-15 | 2009-12-29 | Valeant Pharmaceuticals North America | Nucleoside analogs with carboxamidine modified monocyclic base |
US6455508B1 (en) * | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
US6680059B2 (en) | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US6858590B2 (en) | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
ATE375804T1 (de) | 2000-08-17 | 2007-11-15 | Tripep Ab | Ribavirin-enthaltende vakzine |
AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
RU2005133093A (ru) * | 2003-03-28 | 2006-07-27 | Фармассет, Инк. (Us) | Соединения для лечения флавивирусных инфекций |
US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
US20070184068A1 (en) | 2005-12-14 | 2007-08-09 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
BRPI0708363A2 (pt) * | 2006-03-09 | 2011-05-24 | Om Pharma | processo para o tratamento de animais de sangue quente, incluindo seres humanos, sofrendo de uma doença relativa a uma superprodução de citocinas inflamatórias |
PL2032592T3 (pl) | 2006-06-12 | 2013-11-29 | Kuros Biosciences Ag | Sposoby pakowania oligonukleotydów do cząstek wirusopodobnych z bakteriofagów RNA |
WO2009022236A2 (en) | 2007-08-16 | 2009-02-19 | Tripep Ab | Immunogen platform |
SG10201610936RA (en) | 2011-12-22 | 2017-02-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
EA027929B1 (ru) | 2012-05-25 | 2017-09-29 | Янссен Сайенсиз Айрлэнд Юси | Нуклеозиды на основе урацила и спирооксетана |
EP3421482A1 (en) | 2012-12-21 | 2019-01-02 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
TW201524990A (zh) | 2013-10-11 | 2015-07-01 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
EP3467501B1 (en) | 2014-05-16 | 2020-11-04 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2181673T3 (es) * | 1991-05-01 | 2003-03-01 | Jackson H M Found Military Med | Procedimiento de tratamiento de las enfermedades respiratorias infecciosas. |
-
1997
- 1997-01-21 HU HU9900681A patent/HU220105B/hu not_active IP Right Cessation
- 1997-01-21 CA CA002246162A patent/CA2246162C/en not_active Expired - Lifetime
- 1997-01-21 UA UA98073815A patent/UA46815C2/uk unknown
- 1997-01-21 AT AT97904765T patent/ATE216886T1/de not_active IP Right Cessation
- 1997-01-21 SK SK1004-98A patent/SK283342B6/sk not_active IP Right Cessation
- 1997-01-21 DK DK97904765T patent/DK0879056T3/da active
- 1997-01-21 SI SI9720013A patent/SI9720013A/sl not_active IP Right Cessation
- 1997-01-21 CZ CZ19982329A patent/CZ293584B6/cs not_active IP Right Cessation
- 1997-01-21 IL IL12508897A patent/IL125088A0/xx unknown
- 1997-01-21 ES ES97904765T patent/ES2172764T3/es not_active Expired - Lifetime
- 1997-01-21 BR BR9707154A patent/BR9707154A/pt not_active Application Discontinuation
- 1997-01-21 EP EP97904765A patent/EP0879056B1/en not_active Revoked
- 1997-01-21 WO PCT/US1997/000600 patent/WO1997026883A1/en active IP Right Grant
- 1997-01-21 NZ NZ330784A patent/NZ330784A/xx unknown
- 1997-01-21 PL PL97328003A patent/PL187439B1/pl not_active IP Right Cessation
- 1997-01-21 KR KR1019980705645A patent/KR100298158B1/ko not_active IP Right Cessation
- 1997-01-21 CN CNB971917760A patent/CN1190198C/zh not_active Expired - Fee Related
- 1997-01-21 RU RU98115594/14A patent/RU2186569C2/ru active
- 1997-01-21 DE DE69712316T patent/DE69712316T2/de not_active Revoked
- 1997-01-21 PT PT97904765T patent/PT879056E/pt unknown
-
1998
- 1998-07-22 NO NO983372A patent/NO983372L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0879056A4 (en) | 1999-01-13 |
CZ293584B6 (cs) | 2004-06-16 |
BR9707154A (pt) | 1999-05-25 |
CN1190198C (zh) | 2005-02-23 |
UA46815C2 (uk) | 2002-06-17 |
DE69712316T2 (de) | 2003-01-02 |
SI9720013A (sl) | 1999-06-30 |
AU1747897A (en) | 1997-08-20 |
PL328003A1 (en) | 1999-01-04 |
SK283342B6 (sk) | 2003-06-03 |
KR100298158B1 (ko) | 2001-09-06 |
ATE216886T1 (de) | 2002-05-15 |
KR19990081930A (ko) | 1999-11-15 |
RU2186569C2 (ru) | 2002-08-10 |
AU700642B2 (en) | 1999-01-14 |
SK100498A3 (en) | 2001-03-12 |
IL125088A0 (en) | 1999-01-26 |
HUP9900681A2 (hu) | 1999-07-28 |
PL187439B1 (pl) | 2004-07-30 |
HUP9900681A3 (en) | 1999-12-28 |
CZ232998A3 (cs) | 1999-04-14 |
CN1209747A (zh) | 1999-03-03 |
PT879056E (pt) | 2002-10-31 |
HU220105B (hu) | 2001-10-28 |
EP0879056A1 (en) | 1998-11-25 |
WO1997026883A1 (en) | 1997-07-31 |
DE69712316D1 (en) | 2002-06-06 |
DK0879056T3 (da) | 2002-08-19 |
NO983372L (no) | 1998-09-21 |
CA2246162C (en) | 2000-04-04 |
CA2246162A1 (en) | 1997-07-31 |
NO983372D0 (no) | 1998-07-22 |
NZ330784A (en) | 1999-02-25 |
EP0879056B1 (en) | 2002-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2172764T3 (es) | Modulacion de la expresion de citoquina th1/th2 por ribavirina en linfocitos t activados. | |
ATE96308T1 (de) | Dosierform fuer verabreichung in der humanmedizin. | |
ATE435294T1 (de) | Verabreichung von biologisch aktiven polypeptiden | |
FI946004A (fi) | Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio | |
ATE111931T1 (de) | Verwendung alkylierter polyethylenimine als gallensäureadsorbierende arzneimittel sowie pharmazeutische präparate. | |
DK0679092T3 (da) | Cytokindæmpende midler | |
BR0108402A (pt) | Análogos de nucleosìdeo com base monocìclica carboxamidina modificado | |
GT200000111A (es) | Procedimiento para la obtencion de preparados farmaceuticos solidos de disgregacion rapida. | |
DK0443224T3 (da) | Anvendelse af thrombospondin til fremskyndelse af sårheling | |
ES2016620B3 (es) | Sistema para liberar medicamentos con bioaceptabilidad mejorada. | |
ES2103493T3 (es) | Uso de parathormona, de sus fragmentos biologicamente activos y de peptidos relacionados para el tratamiento del embarazo. | |
ES2095216T3 (es) | Sistema transdermal con cesion escalonada del principio activo y su empleo para la administracion cosmetica local o sistemica del principio activo. | |
ES2054718T3 (es) | El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica. | |
ES2061787T3 (es) | Combinacion de inhibidores de la enzima de conversion de la angiotensina con moduladores del canal del potasio, asi como su empleo en medicamentos. | |
ATE223701T1 (de) | Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen | |
ES2061218T3 (es) | Composiciones farmaceuticas estabilizadas. | |
FI924215A (fi) | Anvaendningen av il-4 foer oekning av immunreaktionen foerorsakad infektiosa antigen aemnen | |
MX9307733A (es) | Restauracion de la funcion inmunologica en pacientes asintomaticos de vih-positivo. | |
ES2165366T3 (es) | Procedimientos y composiciones para inhibir la inflamacion mediada por celulas endoteliales y fibrinogeno. | |
ES2058601T3 (es) | Formulaciones que contienen heparina. | |
ES2056949T3 (es) | Pasta dentifrica a base de arcilla. | |
IT1244529B (it) | Peptidi sintetici atti a potenziare l'infettivita' del virus hiv-1 | |
IT8648494A0 (it) | Formulazioni farmaceutiche a liberazione prolungata della sostanza attiva | |
BG50740A1 (en) | Gel medicamentous form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 879056 Country of ref document: ES |